Skip to main content

Lenvima Side Effects

Generic name: lenvatinib

Medically reviewed by Drugs.com. Last updated on Feb 13, 2024.

Note: This document contains side effect information about lenvatinib. Some dosage forms listed on this page may not apply to the brand name Lenvima.

Applies to lenvatinib: capsule oral, oral capsule.

Serious side effects of Lenvima

Along with its needed effects, lenvatinib (the active ingredient contained in Lenvima) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lenvatinib:

More common

Less common

Incidence not known

Other side effects of Lenvima

Some side effects of lenvatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lenvatinib: oral capsule.

Cardiovascular

Very common (10% or more): Hypertension (73%)

Common (1% to 10%): Hypotension, QT prolongation, arterial thromboembolic event, cardiac dysfunction (cardiac failure, decreased ventricular function, pulmonary edema), myocardial infarction, cerebrovascular accident[Ref]

Renal

Very common (10% or more): Proteinuria (34%), renal impairment (14%)

Common (1% to 10%): Increased creatinine, renal failure

Postmarketing reports: Nephrotic syndrome[Ref]

Hematologic

Very common (10% or more): Hemorrhagic events (35%)

Common (1% to 10%): Decreased platelet count

Postmarketing reports: Arterial (including aortic) aneurysms, dissections, and rupture, impaired wound healing[Ref]

Hepatic

Common (1% to 10%): Hyperbilirubinemia, increased alkaline phosphatase, increased ALT, increased AST

Very rare (less than 0.01%): Hepatic failure, acute hepatitis

Postmarketing reports: Cholecystitis[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (67%), nausea (47%), stomatitis (41%), vomiting (36%), abdominal pain (31%), constipation (29%), oral pain (25%), dry mouth (17%), dyspepsia (13%)

Common (1% to 10%): GI perforation/fistula, increased serum amylase, increased lipase

Postmarketing reports: Pancreatitis, increased amylase[Ref]

Nervous system

Very common (10% or more): Headache (38%), dysgeusia (18%), dizziness (15%)

Common (1% to 10%): Reversible posterior leukoencephalopathy syndrome[Ref]

Endocrine

Very common (10% or more): TSH suppression impairment (up to 88%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (54%), weight decreased (51%)

Common (1% to 10%): Dehydration, hypoalbuminemia, hypomagnesemia, hypoglycemia, hypocalcemia, hypercalcemia, hyperkalemia, hypercholesterolemia[Ref]

Dermatologic

Very common (10% or more): Palmar-plantar erythrodysesthesia (32%), rash (21%), alopecia (12%)

Common (1% to 10%): Hyperkeratosis[Ref]

Genitourinary

Very common (10% or more): Urinary tract infections (11%)[Ref]

Immunologic

Very common (10% or more): Dental and oral infections (10%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia/myalgia (62%)

Uncommon (0.1% to 1%): Osteonecrosis of the jaw[Ref]

Other

Very common (10% or more): Fatigue (67%), peripheral edema (21%)[Ref]

Psychiatric

Very common (10% or more): Insomnia (12%)[Ref]

Respiratory

Very common (10% or more): Dysphonia (31%), cough (24%), epistaxis (12%)

Common (1% to 10%): Pulmonary embolism[Ref]

Frequently asked questions

References

1. Product Information. Lenvima (lenvatinib). Eisai Inc. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.